Comparison of pegaspargase with concurrent radiation vs. P-GEMOX with sequential radiation in early-stage NK/T-cell lymphoma
Oncology Research · 2025 · 33 (4) · 965-974
DOI: 10.32604/or.2024.057065 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Oncology Research, 2025. Verfasst von Demei Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Asparaginase, Polyethylene Glycols, Lymphoma, Extranodal NK-T-Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
The optimal treatment strategy for early-stage natural killer/T-cell lymphoma (NKTCL) remains unclear. This study aimed to evaluate and compare the clinical outcomes and adverse events (AEs) associated with two treatment regimens for early-stage NKTCL: pegaspargase with concurrent radiation therapy (P+CCRT) and pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) with sequential radiation therapy (SERT). Propensity score matching (PSM) was employed to ensure balanced comparison between these regimens.
Methods
We assessed the efficacy of P+CCRT from a phase II trial and P-GEMOX combined with SERT using real-world data. PSM was conducted at a 1:1 ratio with a caliper of 0.18 to align baseline characteristics between the treatment groups. Key outcomes analyzed included overall response rate (ORR), complete response rate (CR), progression-free survival (PFS), overall survival (OS), and AEs.
Results
Following PSM, the study included 52 patients, with 26 in each treatment group. Baseline characteristics were balanced between the cohorts. The ORR for P+CCRT group was 100.0% compared to 88.5% for P-GEMOX+ SERT group, and the CR rates was 100.0% vs. 76.9%, respectively. The 3-year OS and PFS rates were both 92.3% for P+CCRT, while P-GEMOX showed 92.3% OS and 80.8% PFS. Adverse events, including hematological toxicity, hepatotoxicity, and coagulation dysfunction, were comparable between the two regimens.
Conclusion
P+CCRT is associated with comparable clinical outcomes compared to P-GEMOX + SERT in early-stage NKTCL, with comparable adverse events. Additionally, P+CCRT offers the benefit of a more streamlined treatment regimen with a shorter cycle. Given these encouraging results, further cohort studies are needed to validate these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
- Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Zitieren
APA
Feng, D., Bai, S., Chen, G., Fu, B., Song, C., Tang, H., Wang, L., & Wang, H. (2025). Comparison of pegaspargase with concurrent radiation vs. P-GEMOX with sequential radiation in early-stage NK/T-cell lymphoma. Oncology Research, 33(4), 965-974. https://doi.org/10.32604/or.2024.057065
Vancouver
Feng D, Bai S, Chen G, Fu B, Song C, Tang H, et al. Comparison of pegaspargase with concurrent radiation vs. P-GEMOX with sequential radiation in early-stage NK/T-cell lymphoma. Oncology Research. 2025;33(4):965-974. doi:10.32604/or.2024.057065
BibTeX
@article{Feng2025,
author = {Feng, Demei and Bai, Shenrui and Chen, Guanjun and Fu, Bibo and Song, Cailu and Tang, Hailin and Wang, Liang and Wang, Hua},
title = {Comparison of pegaspargase with concurrent radiation vs. P-GEMOX with sequential radiation in early-stage NK/T-cell lymphoma},
journal = {Oncology Research},
year = {2025},
volume = {33},
number = {4},
pages = {965--974},
doi = {10.32604/or.2024.057065}
}
EUVIMED